Who is sponsoring NCT01471171?

NCT01471171 is sponsored by AstraZeneca.

What condition does NCT01471171 study?

NCT01471171 studies Chronic Obstructive Pulmonary Disease (COPD).

What drugs are being tested in NCT01471171?

Interventions: Aclidinium Bromide, Placebo.

What is the status of NCT01471171?

NCT01471171 is currently COMPLETED.

Last reviewed 2016-11-16 · How we verify

A Multiple Dose, Randomised, Double-blind, Placebo Controlled, 2 Period Crossover Clinical Trial to Assess the Effect of Aclidinium Bromide 400 μg BID on Exercise Endurance in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01471171 Phase 3 COMPLETED Results posted

The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg twice a day (BID) administered twice a day versus placebo on exercise endurance and on hyperinflation and dyspnoea at rest and during exercise after 3 weeks of treatment.

Details

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	COMPLETED
Enrolment	112
Start date	2011-11
Completion	2012-06

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

Aclidinium Bromide
Placebo

Primary outcomes

Change From Baseline in Endurance Time (Seconds) — Week 3
Change from baseline in endurance time during constant work rate cycle ergometry to symptom limitation at 75% of Maximum Work load (Wmax) after 3 weeks of treatment.

Countries

Germany, Spain, United Kingdom